Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy

Members of the Lung Cancer Disease Site Group, 2003 Payne, 1994, Small cell lung cancer: the role of thoracic irradiation and its timing in relation the chemotherapy, Bull Cancer, 81, 119 Browman, 1998, Progress of clinical oncology guidelines development using the practice guidelines development cycle: the role of practitioner feedback, J Clin Oncol, 16, 1226, 10.1200/JCO.1998.16.3.1226 Browman, 1995, The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation, J Clin Oncol, 13, 502, 10.1200/JCO.1995.13.2.502 Sun, 2017 Members of the Lung Cancer Disease Site Group, 2003 Schünemann H, Brozek J, Guyatt G, Oxman AD, editors. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. [Accessed 1 June 2017]. Spiro, 2006, Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis, J Clin Oncol, 24, 3823, 10.1200/JCO.2005.05.3181 Sun, 2013, Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer, Ann Oncol, 24, 2088, 10.1093/annonc/mdt140 Schild, 2004, Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer, Int J Radiat Oncol Biol Phys, 59, 943, 10.1016/j.ijrobp.2004.01.055 Faivre-Finn, 2017, Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial, Lancet Oncol, 18, 1116, 10.1016/S1470-2045(17)30318-2 Bogart, 2000 Pignon, 1992, A meta-analysis of thoracic radiotherapy for small-cell lung cancer, N Engl J Med, 327, 1618, 10.1056/NEJM199212033272302 Takada, 2002, Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104, J Clin Oncol, 20, 3054, 10.1200/JCO.2002.12.071 Lebeau, 1999, A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma, Cancer, 86, 1480, 10.1002/(SICI)1097-0142(19991015)86:8<1480::AID-CNCR14>3.0.CO;2-O Blackstock, 2005, Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial, Clin Lung Cancer, 6, 287, 10.3816/CLC.2005.n.007 Faivre-Finn, 2011, Long-term toxicity report from a phase II study of accelerated twice-daily (BD) versus high dose once-daily (OD) thoracic radiotherapy (RT) with concurrent chemotherapy for limited-stage small cell lung cancer (LS-SCLC), Int J Radiat Oncol Biol Phys, 1, S589, 10.1016/j.ijrobp.2011.06.1104 Gronberg, 2016, Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer, Acta Oncol, 55, 591, 10.3109/0284186X.2015.1092584 Murray, 1993, Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 11, 336, 10.1200/JCO.1993.11.2.336 Turrisi, 1999, Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide, N Engl J Med, 340, 265, 10.1056/NEJM199901283400403 Maksymiuk, 1994, Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial, J Clin Oncol, 12, 70, 10.1200/JCO.1994.12.1.70 Leyvraz, 2008, A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial, J Natl Cancer Inst, 100, 533, 10.1093/jnci/djn088 Sculier, 2008, A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer, Ann Oncol, 19, 1691, 10.1093/annonc/mdn354 Jeremic, 1999, Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study, J Clin Oncol, 17, 2092, 10.1200/JCO.1999.17.7.2092 Gore, 2017, Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937, J Thorac Oncol, 12, 1561, 10.1016/j.jtho.2017.06.015 Narayan, 2015, A prospective randomized phase III study of continuum chemotherapy versus chemo-radiotherapy in ES-SCLC in Asian Indian, J Thorac Oncol, 2, S193 Slotman, 2015, Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial, Lancet, 385, 36, 10.1016/S0140-6736(14)61085-0 Slotman, 2015, Which patients with extensive stage small-cell lung cancer should and should not receive thoracic radiotherapy?, Transl Lung Cancer Res, 4, 292 Noda, 2002, Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer, N Engl J Med, 346, 85, 10.1056/NEJMoa003034 Kim, 2013, Phase III trial comparing irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP) in Korean patients with extensive disease (ED) small cell lung cancer (SCLC), J Thorac Oncol, 8, S219 Eckardt, 2006, Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer, J Clin Oncol, 24, 2044, 10.1200/JCO.2005.03.3332 Fink, 2012, Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial, J Thorac Oncol, 7, 1432, 10.1097/JTO.0b013e318260de75 Mau-Soerensen, 2014, Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum, J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.7519 Hanna, 2006, Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lime cancer, J Clin Oncol, 24, 2038, 10.1200/JCO.2005.04.8595 Hermes, 2008, Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial, J Clin Oncol, 26, 4261, 10.1200/JCO.2007.15.7545 Lara, 2009, Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124, J Clin Oncol, 27, 2530, 10.1200/JCO.2008.20.1061 Schmittel, 2011, A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer, Ann Oncol, 22, 1798, 10.1093/annonc/mdq652 Shi, 2015, Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: a multicenter randomized controlled clinical trial, Thorac Cancer, 6, 785, 10.1111/1759-7714.12303 Zatloukal, 2010, A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease, Ann Oncol, 21, 1810, 10.1093/annonc/mdq036 Heigener, 2009, Am J Clin Oncol, 32, 61, 10.1097/COC.0b013e31817be954 Baka, 2010, Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer, Anticancer Res, 30, 3031 Ignatiadis, 2005, Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a phase III trial of the Hellenic Oncology Research Group, Clin Lung Cancer, 7, 183, 10.3816/CLC.2005.n.034 Masutani, 2000, Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?, Oncol Rep, 7, 305 Schaefer, 2003, Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers, Am J Clin Oncol, 26, 236, 10.1097/01.COC.0000018038.28645.46 Sculier, 2001, A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics, Br J Cancer, 85, 1444, 10.1054/bjoc.2001.2114 Sekine, 2003, Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI), Ann Oncol, 14, 709, 10.1093/annonc/mdg213 Ueoka, 1998, Cancer, 83, 283, 10.1002/(SICI)1097-0142(19980715)83:2<283::AID-CNCR12>3.0.CO;2-P Veslemes, 1998, Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide, J Chemother, 10, 136 Xiao, 2015, Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer, Onco Targets Ther, 8, 2209, 10.2147/OTT.S89606